BayMark Health Services Acquires Tri-City Institute in Los Angeles, CA
LOS ANGELES, Oct. 03, 2018
LOS ANGELES, Oct. 03, 2018 /PRNewswire-PRWeb/ -- BayMark Health Services announced last week the acquisition of Tri-City Institute, a medication-assisted treatment provider in Los Angeles, CA. Tri City, established more than 25 years ago, built a strong reputation by providing discreet, patient-focused medication-assisted treatment services.
"Tri City was opened in 1992 to fulfill a need for confidential, effective treatment services for the highly stigmatized disease of opioid use disorder," stated Carolyn Perry, founder of Tri City. We have continued to work to advocate for our patients, and others struggling with this devastating disease. We feel that BayMark brings the experience and expertise to continue our legacy and maintain the level of care our patients have come to expect from Tri City."
MedMark Treatment Centers provides outpatient medication-assisted treatment (MAT) for opiate addiction and dependency. Medication-assisted treatment combines medications, such as methadone and buprenorphine, with addiction counseling and behavioral therapies. This approach provides an evidence-based, comprehensive treatment plan, individualized to meet the needs of each patient.
David K. White, Ph.D., Chief Executive Officer of BayMark Health Services, noted, "The need for proven treatment options for opioid addiction has never been greater. BayMark sees the need for expanded access to treatment and looks to work with organizations who have established a foundation of excellence in their clinical practices. We have known Carolyn Perry and Tri City Institute for many years and her commitment and passion for patient care makes this a great opportunity for BayMark. We are excited to continue the legacy she created, now as a member of the BayMark/MedMark family."
For more information on MedMark Treatment Centers visit: http://www.MedMark.com.
About BayMark Health Services:
BayMark Health Services provides medication-assisted treatment to more than 46,000 patients in recovery from opioid use disorder. Our outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of prescription pain medication or other opiates. The BayMark continuum of patient-focused services includes highly structured opioid treatment programs utilizing methadone or buprenorphine and office-based buprenorphine programs, both of which incorporate counseling as part of an individualized treatment plan; as well as, ambulatory withdrawal management services with naltrexone therapy, residential treatment and recovery support services.
SOURCE BayMark Health Services